Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$1.47
+3.9%		$0.91
$0.62
▼
$12.80
$9.76M1.2252,649 shs173,683 shs
Imunon, Inc. stock logo
IMNN
Imunon
$1.61
-1.2%		$1.73
$1.47
▼
$6.35
$9.04M1.9793,409 shs17,173 shs
Immuron stock logo
IMRN
Immuron
$1.17
+2.2%		$1.13
$0.68
▼
$2.39
$9.40M1.15114,681 shs3,958 shs
Onconetix, Inc. stock logo
ONCO
Onconetix
$0.64
-0.2%		$0.88
$0.62
▼
$209.50
$2.53M2.69657,223 shs72,852 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
+0.71%+18.49%+124.84%+24.78%-88.35%
Imunon, Inc. stock logo
IMNN
Imunon
-1.81%+3.16%+6.54%-29.13%-73.88%
Immuron stock logo
IMRN
Immuron
0.00%-4.20%+7.55%-5.79%-35.23%
Onconetix, Inc. stock logo
ONCO
Onconetix
-0.31%-9.85%-21.24%-45.21%-99.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$1.47
+3.9%		$0.91
$0.62
▼
$12.80
$9.76M1.2252,649 shs173,683 shs
Imunon, Inc. stock logo
IMNN
Imunon
$1.61
-1.2%		$1.73
$1.47
▼
$6.35
$9.04M1.9793,409 shs17,173 shs
Immuron stock logo
IMRN
Immuron
$1.17
+2.2%		$1.13
$0.68
▼
$2.39
$9.40M1.15114,681 shs3,958 shs
Onconetix, Inc. stock logo
ONCO
Onconetix
$0.64
-0.2%		$0.88
$0.62
▼
$209.50
$2.53M2.69657,223 shs72,852 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
+0.71%+18.49%+124.84%+24.78%-88.35%
Imunon, Inc. stock logo
IMNN
Imunon
-1.81%+3.16%+6.54%-29.13%-73.88%
Immuron stock logo
IMRN
Immuron
0.00%-4.20%+7.55%-5.79%-35.23%
Onconetix, Inc. stock logo
ONCO
Onconetix
-0.31%-9.85%-21.24%-45.21%-99.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
1.80
Reduce$73.004,882.94% Upside
Imunon, Inc. stock logo
IMNN
Imunon
2.00
Hold$10.00520.73% Upside
Immuron stock logo
IMRN
Immuron
1.00
SellN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ONCO, FBLG, IMRN, and IMNN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2026
Onconetix, Inc. stock logo
ONCO
Onconetix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
8/20/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
8/11/2026
Onconetix, Inc. stock logo
ONCO
Onconetix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
8/4/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00 ➝ $6.00
8/4/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeUnderperform
7/24/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/17/2026
Imunon, Inc. stock logo
IMNN
Imunon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/15/2026
Onconetix, Inc. stock logo
ONCO
Onconetix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/7/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
6/29/2026
Onconetix, Inc. stock logo
ONCO
Onconetix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
6/24/2026
Immuron stock logo
IMRN
Immuron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$0.70 per shareN/A
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/A$0.35 per shareN/A
Immuron stock logo
IMRN
Immuron
$4.72M1.99N/AN/A$0.78 per share1.49
Onconetix, Inc. stock logo
ONCO
Onconetix
$810K3.12N/AN/A$3.41 per share0.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$18.65M-$5.19N/AN/AN/AN/A-536.78%-225.12%10/30/2026 (Estimated)
Imunon, Inc. stock logo
IMNN
Imunon
-$14.49M-$3.83N/AN/AN/AN/A-358.01%-132.91%11/12/2026 (Estimated)
Immuron stock logo
IMRN
Immuron
-$3.38MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)
Onconetix, Inc. stock logo
ONCO
Onconetix
-$14.03M$248.120.00N/AN/A-1,575.89%-91.95%-53.76%11/12/2026 (Estimated)

Latest ONCO, FBLG, IMRN, and IMNN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/28/2026N/A
Immuron stock logo
IMRN
Immuron
-$0.0037N/AN/AN/A$2.75 millionN/A
8/13/2026Q2 2026
Onconetix, Inc. stock logo
ONCO
Onconetix
-$4,505.00-$1.28+$4,503.72-$1.28$0.02 million$0.02 million
8/11/2026Q2 2026
Imunon, Inc. stock logo
IMNN
Imunon
-$0.8675-$0.54+$0.3275-$0.54N/AN/A
7/31/2026Q2 2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.93-$0.66+$0.27-$0.66N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/AN/A
Immuron stock logo
IMRN
Immuron
N/AN/AN/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
2.64
2.64
Imunon, Inc. stock logo
IMNN
Imunon
2.86
1.82
1.82
Immuron stock logo
IMRN
Immuron
N/A
8.04
6.83
Onconetix, Inc. stock logo
ONCO
Onconetix
N/A
2.21
2.14

Institutional Ownership

CompanyInstitutional Ownership
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
Imunon, Inc. stock logo
IMNN
Imunon
4.47%
Immuron stock logo
IMRN
Immuron
0.12%
Onconetix, Inc. stock logo
ONCO
Onconetix
23.89%

Insider Ownership

CompanyInsider Ownership
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
7.30%
Imunon, Inc. stock logo
IMNN
Imunon
2.83%
Immuron stock logo
IMRN
Immuron
7.01%
Onconetix, Inc. stock logo
ONCO
Onconetix
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
106.66 million6.17 millionN/A
Imunon, Inc. stock logo
IMNN
Imunon
305.61 million5.45 millionNot Optionable
Immuron stock logo
IMRN
Immuron
N/A8.07 million7.51 millionNot Optionable
Onconetix, Inc. stock logo
ONCO
Onconetix
123.95 million3.94 millionN/A

Recent News About These Companies

Head-To-Head Contrast: Onconetix (NASDAQ:ONCO) vs. enGene (NASDAQ:ENGN)
August 25 at 4:00 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30982357
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340287/0/en/onconetix-acquisition-target-realbotix-secures-agreement-for-humanoid-robot-appearance-on-emmy-award-winning-streaming-series.html
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339298/0/en/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag.html
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323233/0/en/onconetix-highlights-realbotix-partnership-with-bloom-services-to-launch-uk-pilot-using-humanoid-robots-to-combat-elderly-social-isolation.html
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
June 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/onconetix-highlights-realbotix-s-launch-of-humanoid-robot-and-ai-teachers-assistant-pilot-program-in-new-york-state-school-district-1036271876
Onconetix Announces Realbotix Optio and M-Series Humanoid Robot Pilot at Salamanca City Central School District
June 24, 2026  |  quiverquant.comQ
Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316830/0/en/onconetix-highlights-realbotix-s-launch-of-humanoid-robot-and-ai-teachers-assistant-pilot-program-in-new-york-state-school-district.html
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
June 23, 2026  |  accessnewswire.comA
Onco-Innovations Announces Non-Brokered LIFE Offering
June 19, 2026  |  accessnewswire.comA
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
June 19, 2026  |  accessnewswire.comA
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
June 16, 2026  |  accessnewswire.comA
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297397/0/en/onconetix-inc-announces-1-for-10-reverse-stock-split.html
Realbotix Provides Update on Nasdaq Listing
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519598336/en/realbotix-provides-update-on-nasdaq-listing/
Onconetix Inc. Reports New Clinical Data Supporting Proclarix® in Reducing Overdiagnosis and Launches PRIME Study with Labcorp
May 13, 2026  |  quiverquant.comQ
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294088/0/en/onconetix-reports-q1-2026-progress-at-proteomedix-ag-including-two-new-peer-reviewed-publications-and-initiation-of-u-s-validation-study.html
Onconetix Shareholders Approve Flexible Reverse Stock Split Authorization
May 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1724138/onconetix-shareholders-approve-flexible-reverse-stock-split-authorization/
Onconetix Reshapes Board Leadership With New Chairman, Director
April 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onconetix-reshapes-board-leadership-with-new-chairman-director?utm_source=marketbeat.com&utm_medium=referral
Onconetix: HRT financial, 10% owner, sells $110,169 in stock
April 23, 2026  |  investing.comhttps://www.investing.com/news/insider-trading-news/onconetix-hrt-financial-10-owner-sells-110169-in-stock-93CH-4627215
Insider Selling: Onconetix (NASDAQ:ONCO) Major Shareholder Sells 49,710 Shares of Stock
April 23, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-onco-insider-buying-and-selling-2026-04-23/
Onconetix (NASDAQ:ONCO) Major Shareholder Acquires $25,284.28 in Stock
April 22, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-onco-insider-buying-and-selling-2026-04-22/

New MarketBeat Followers Over Time

Media Sentiment Over Time

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$1.46 +0.06 (+3.90%)
As of 02:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Imunon stock logo

Imunon NASDAQ:IMNN

$1.61 -0.02 (-1.17%)
As of 02:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Immuron stock logo

Immuron NASDAQ:IMRN

$1.16 +0.03 (+2.19%)
As of 02:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Onconetix stock logo

Onconetix NASDAQ:ONCO

$0.64 0.00 (-0.16%)
As of 02:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas